Inclusion Criteria:

- Age greater than or equal to 18 years.

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

- Consent for peripheral blood sampling for analysis of circulating tumor cells.

- Patients must have adequate organ and marrow function as defined by the protocol.

- Female patients with histologically confirmed adenocarcinoma of the breast with
recurrent local-regional disease, or metastatic disease that have progressed after
treatment with regimens that include an anthracycline, a taxane, or trastuzumab.

- Human Epidermal growth factor Receptor 2 (HER2) positive in the primary or secondary
tumor tissue as defined by:

- Grade 3plus staining intensity (on a scale of 0 to 3) by means of
Immunohistochemistry (IHC) analysis OR

- Gene amplification on fluorescence in situ hybridization (FISH) greater than or
equal to 2.2.

- Patients must have measurable disease by the Response Evaluation Criteria In Solid
Tumors (RECIST)criteria at the time of enrollment.

- Prior trastuzumab therapy is allowed. Trastuzumab should be stopped at least 4 weeks
prior to enrollment.

Exclusion Criteria:

- Patients receiving any other investigational agents.

- Prior exposure to lapatinib, vorinostat, or other Histone deacetylase (HDAC)
inhibitors. Prior valproic acid exposure is allowed providing this is a greater than
or equal to 30 days wash-out period.

- History of allergic reactions or hypersensitivity to compounds of similar chemical or
biologic composition to vorinostat or lapatinib.

- Patients with history of clinically significant or uncontrolled cardiac disease, as
defined by the protocol, or any significant cardiac condition that in the judgment of
the investigator is unsuitable.

- Significant chronic or recent (less than 30 days) acute gastrointestinal disorder
with diarrhea as a major symptom (e.g. Crohn's disease, malabsorption, or Grade 2 or
greater diarrhea of any etiology at baseline).

- Prior exposure to more than 360 mg/m2 doxorubicin or liposomal doxorubicin, more than
120 mg/m2 mitoxantrone, or more than 90 mg/m2 idarubicin, or elevated baseline
cardiac troponin T (more than upper limit of normal).

- Patients with active Central Nervous System (CNS) metastasis and/or carcinomatous
meningitis are excluded. Patients with CNS metastasis who have completed a course of
therapy would be eligible for the study provided they are clinically stable for 3
weeks prior to entry as defined as: (1) no evidence of new or enlarging CNS
metastasis and (2) off steroids and/or anticonvulsants, for at least 4 weeks before
an enrollment.

- Female patient that is pregnant or breastfeeding or expecting to conceive during the
study. Women able to have children must have a negative pregnancy test prior to
enrollment. All patients must use two effective methods of contraception (including a
barrier method) during treatment and for 12 weeks after stopping treatment.

- The patient is known to be Human immunodeficiency virus (HIV), Hepatitis B, or
Hepatitis C-positive (test results are not required in order to participate).

- Patients with current active hepatic or biliary disease (with exception of patients
with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic
liver disease per investigator assessment)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirement.

- Previous or current systemic malignancy within the past 3 years other than the
following: Female- breast cancer or adequately treated carcinoma in-situ of the
cervix, or Female and Male- basal/squamous carcinoma of the skin.